Arjuna Capital Has $6.50 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Arjuna Capital lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) by 3.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 12,836 shares of the medical research company’s stock after buying an additional 485 shares during the period. Thermo Fisher Scientific comprises about 2.3% of Arjuna Capital’s holdings, making the stock its 8th largest position. Arjuna Capital’s holdings in Thermo Fisher Scientific were worth $6,497,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Savant Capital LLC boosted its holdings in Thermo Fisher Scientific by 0.5% during the 4th quarter. Savant Capital LLC now owns 3,627 shares of the medical research company’s stock valued at $1,997,000 after acquiring an additional 18 shares during the period. 1776 Wealth LLC boosted its stake in shares of Thermo Fisher Scientific by 2.4% in the 4th quarter. 1776 Wealth LLC now owns 799 shares of the medical research company’s stock worth $440,000 after buying an additional 19 shares during the last quarter. Dover Advisors LLC boosted its stake in shares of Thermo Fisher Scientific by 0.6% in the 2nd quarter. Dover Advisors LLC now owns 3,168 shares of the medical research company’s stock worth $1,654,000 after buying an additional 20 shares during the last quarter. Westbourne Investment Advisors Inc. boosted its stake in shares of Thermo Fisher Scientific by 3.6% in the 2nd quarter. Westbourne Investment Advisors Inc. now owns 568 shares of the medical research company’s stock worth $296,000 after buying an additional 20 shares during the last quarter. Finally, Klingman & Associates LLC raised its holdings in Thermo Fisher Scientific by 5.0% in the 2nd quarter. Klingman & Associates LLC now owns 439 shares of the medical research company’s stock worth $229,000 after purchasing an additional 21 shares during the period. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the sale, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the transaction, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the transaction, the chief executive officer now directly owns 49,155 shares in the company, valued at $27,311,992.65. The disclosure for this sale can be found here. 0.32% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on TMO shares. Barclays cut Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and raised their target price for the stock from $475.00 to $555.00 in a report on Wednesday, January 24th. Citigroup raised their price target on Thermo Fisher Scientific from $530.00 to $575.00 and gave the company a “buy” rating in a report on Monday, December 11th. Royal Bank of Canada raised their price target on Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. StockNews.com raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Thursday, October 26th. Finally, JPMorgan Chase & Co. reduced their target price on Thermo Fisher Scientific from $670.00 to $630.00 and set an “overweight” rating on the stock in a report on Tuesday, October 17th. Four investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $596.00.

Check Out Our Latest Analysis on Thermo Fisher Scientific

Thermo Fisher Scientific Stock Down 0.7 %

NYSE:TMO traded down $3.81 during trading hours on Monday, reaching $546.94. The company’s stock had a trading volume of 116,415 shares, compared to its average volume of 1,914,795. The stock has a 50 day moving average price of $533.33 and a two-hundred day moving average price of $513.55. The company has a market capitalization of $211.32 billion, a P/E ratio of 35.65, a price-to-earnings-growth ratio of 2.31 and a beta of 0.80. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.39 and a current ratio of 1.75. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $593.17.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last issued its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The business had revenue of $10.89 billion for the quarter, compared to the consensus estimate of $10.73 billion. During the same period in the prior year, the firm posted $5.40 earnings per share. The business’s quarterly revenue was down 4.9% on a year-over-year basis. Equities analysts predict that Thermo Fisher Scientific Inc. will post 21.57 EPS for the current fiscal year.

Thermo Fisher Scientific announced that its Board of Directors has authorized a share repurchase plan on Tuesday, November 14th that authorizes the company to repurchase $4.00 billion in shares. This repurchase authorization authorizes the medical research company to purchase up to 2.2% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s board of directors believes its shares are undervalued.

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Further Reading

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.